Castle Biosciences Inc

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Castle Biosciences posts robust Q4 earnings, eyes growth opportunities ahead

Castle Biosciences reported strong financial performance in Q4 and full-year 2022, driven by revenue growth and test volume increase.
The company's focus on expanding commercial teams, R&D initiatives, and new laboratory openings positions it for future growth.
Challenges lie in convincing commercial payers and maintaining gross margin, requiring strategic actions and evidence-based outcomes.
Opportunities exist in demonstrating patient outcomes, NCCN guideline inclusion, and leveraging cash reserves for growth.

Castle Biosciences reports robust Q1 performance and navigates growth challenges

Castle Biosciences delivered a strong Q1 2023 with notable revenue growth and volume increases, supported by a solid financial position.
The company's focus on dermatology, gastroenterology, and mental health segments, along with positive clinical study results, underpin its market strength.
While facing challenges in sales execution and territory management, Castle Biosciences is strategically positioned to capitalize on growth opportunities in its key product lines.

Castle Biosciences reports robust Q2 growth and navigates coverage challenges

Castle Biosciences delivered strong financial performance in Q2 2023, with revenue and test volume growth surpassing expectations.
Despite challenges in coverage and operational constraints, the company's strategic focus on test value and market expansion presents promising growth prospects.
With a solid financial position, ongoing efforts to address challenges, and capitalize on opportunities, Castle Biosciences is poised for continued success in the precision medicine market.

Castle Biosciences reports stellar Q3 results and eyes market expansion

Castle Biosciences delivered exceptional financial results, raised revenue guidance, and showcased strong growth across its test portfolio. The company's focus on innovation, clinical impact, and market recognition positions it well for future success. While challenges in managing growth and competition exist, Castle Biosciences has opportunities to capitalize on its strengths and expand its market presence.

Castle Biosciences reports stellar 2023 performance and eyes new markets

Castle Biosciences delivered strong financial performance in Q4 and full year 2023, driven by robust revenue growth and impressive test volume results across key tests.
The company showcased clinical efficacy, innovation, and financial discipline, while navigating challenges such as cost pressures and reimbursement uncertainties.
Strategic initiatives like expanding test portfolios, managing costs effectively, and exploring new growth avenues position Castle Biosciences for continued success and market leadership.
With a focus on maintaining profitability, investing in growth, and leveraging opportunities, Castle Biosciences is poised for sustained growth and value creation in the future.

Castle Biosciences excels in Q1 2024, eyes strategic growth opportunities

Castle Biosciences delivered exceptional financial and operational results in Q1 2024, showcasing strong revenue growth, improved margins, and product advancements. While facing some challenges with test volumes and Medicare coverage, the company's solid performance and market position present promising opportunities for future growth.

Castle Biosciences excels in Q2, raises guidance amid test volume surge

Castle Biosciences delivered outstanding financial results in Q2 2024, showcasing strong revenue growth, improved margins, and a significant net income turnaround.
The company's focus on innovation and clinical value in its tests positions it well for sustained growth and market leadership in precision diagnostics.
While facing challenges in maintaining growth momentum and operational efficiency, Castle Biosciences has opportunities to expand its market presence and drive international expansion.
Overall, Castle Biosciences' Q2 performance reflects a resilient and promising trajectory, underpinned by strategic strengths and a commitment to advancing patient care.

Castle Biosciences excels in Q3, poised for sustained growth

Castle Biosciences' Q3 performance reflects strong revenue growth, financial stability, and a positive outlook for future expansion.
The company's focus on product innovation, market penetration, and financial discipline positions it well for continued success.
While challenges exist in maintaining growth and profitability, Castle Biosciences has ample opportunities for further market expansion and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at the JMP Securities Life Sciences Conference on June 16 at 10:30 a.m. Eastern time.

Castle Biosciences to Present at the JMP Securities Life Sciences Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle has been selected as the winner of the “Best New Technology Solution – Dermatology” award in the 6th annual MedTech Breakthrough Awards.

Castle Biosciences' DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that an abstract regarding its DecisionDx®-Melanoma test will be available online during the upcoming 2022 ASCO Annual Meeting.

Data Demonstrating DecisionDx®-Melanoma's Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle announced new data showing that its TissueCypher® test outperformed standard of care in predicting progression in Barrett's esophagus patients.

TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett's Esophagus with Low-Grade Dysplasia

NEW YORK & FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Research to Prevent Blindness and Castle are partnering to increase opportunities for medical students to gain research experiences in ocular cancer.

Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--New data presented at ACMS confirms independent risk-stratification performance of Castle's DecisionDx®-SCC test.

Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has once again teamed up with The Sun Bus as a national sponsor of their mobile clinic.

Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communications Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Capital Markets Kyle Mikson - Canaccord Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences First Quarter 2022 Conference Call. As a reminder, today's call is being recorded.

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2022 Results - Earnings Call Transcript

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2022. “We saw significant progress and execution on our growth initiatives in the first quarter, with record test report volume,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We remain laser-focused on the execution of our three o

Castle Biosciences Reports First Quarter 2022 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that it will collaborate with the Melanoma Research Foundation and The Skin Cancer Foundation during Skin Cancer Awareness Month.

Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that its current U.S. Federal Supply Schedule contract with the Veterans Health Administration was expanded as of April 15, 2022.

Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle announced an independent, peer-reviewed article in Clinical Gastroenterology and Hepatology for its TissueCypher® Barrett's Esophagus Test.

Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett's Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc.

Castle Biosciences Completes Acquisition of AltheaDx

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022.

Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data from a recent study showing patients tested with DecisionDx®-Melanoma had improved survival compared to untested patients.

Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology (EADO) Congress.

Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a poster presentation on its inflammatory skin disease pipeline test at the 4th Annual Revolutionizing Atopic Dermatitis Conference.

Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET.

Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #MA--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that are focused on mental health. IDgenetix® is its PGx test for depression, anxiety and other mental health conditions. “

Castle Biosciences to Acquire AltheaDx

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle Biosciences announced that the Centers for Medicare & Medicaid Services granted ADLT status for the TissueCypher® Barrett's Esophagus test.

Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett's Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on two of its GEP tests for skin cancer at the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022.

Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on DecisionDx®-Melanoma and i31-SLNB at the SSO 2022 International Conference on Surgical Cancer Care, March 9-12.

Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity

Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q4 2021 Results - Earnings Call Transcript

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2021.

Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Castle Biosciences Inc Stock (CSTL)